|
CCNYL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.71299996409857E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.66520000011161E-08 |
| Normal-vs-Stage2 |
1.61939999965277E-07 |
| Normal-vs-Stage3 |
6.94709956228223E-10 |
| Normal-vs-Stage4 |
4.36140012993746E-12 |
| Stage1-vs-Stage2 |
7.228800E-01 |
| Stage1-vs-Stage3 |
8.001600E-02 |
| Stage1-vs-Stage4 |
3.773500E-04 |
| Stage2-vs-Stage3 |
3.925400E-01 |
| Stage2-vs-Stage4 |
2.184500E-02 |
| Stage3-vs-Stage4 |
8.630400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.13109996316518E-09 |
| Normal-vs-AfricanAmerican |
2.39909999999455E-05 |
| Normal-vs-Asian |
2.18910000004957E-06 |
| Caucasian-vs-AfricanAmerican |
6.506000E-01 |
| Caucasian-vs-Asian |
5.203400E-01 |
| AfricanAmerican-vs-Asian |
4.835800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.61260005349106E-09 |
| Normal-vs-Female |
2.93339996737529E-09 |
| Male-vs-Female |
5.292000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.09809999666078E-08 |
| Normal-vs-Age(41-60Yrs) |
1.80710002517515E-10 |
| Normal-vs-Age(61-80Yrs) |
2.36810004938803E-09 |
| Normal-vs-Age(81-100Yrs) |
1.387930E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.476020E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.280760E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.378200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.491200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.228400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.262600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.103170E-01 |
| Classical-VS-Follicular |
1.036430E-01 |
| Classical-VS-Other |
1.077760E-01 |
| Classical-VS-Normal |
3.944199999939E-08 |
| Tall-VS-Follicular |
6.289800E-01 |
| Tall-VS-Other |
3.713000E-01 |
| Tall-VS-Normal |
6.91049995005244E-09 |
| Follicular-VS-Other |
3.090200E-01 |
| Follicular-VS-Normal |
3.49410000932693E-09 |
| Other-VS-Normal |
6.624600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.17810003366736E-09 |
| Normal-vs-N1 |
9.15919995403414E-09 |
| N0-vs-N1 |
5.377600E-01 |
|
|
